Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The impact of atrial natriuretic peptide (ANP) value for predicting paroxysmal atrial fibrillation (pAF) in ischemic stroke patients remains uncertain.
Methods: The consecutive 222 ischemic stroke patients (median 77 [IQR 68-83] years old, 93 females) within 48 hours after onset were retrospectively studied. Plasma ANP and brain natriuretic peptide (BNP) levels were simultaneously measured at admission. Of all, 158 patients had no evidence of atrial fibrillation (AF) (sinus rhythm [SR] group), 25 patients had pAF (pAF group), and the other 39 patients had chronic AF (cAF group). We investigated predicting factors for pAF, with focus on ANP, BNP, and ANP/BNP ratio.
Results: ANP value was significantly higher in the pAF than in the SR group (97 [50-157] mg/dL versus 42 [26-72] mg/dL, P < .05) and further increased in the cAF group (228 [120-392], P < .05 versus pAF and SR groups). Similarly, the BNP value was higher in the pAF than in the SR group (116 [70-238] mg/dL versus 34 [14-72] mg/dL, P < .05) and further increased in the cAF group (269 [199-423], P < .05 versus pAF and SR groups). ANP/BNP ratio was lower in the pAF and cAF groups than in the SR group (.6 [.5-1.2] and .7 [.5-1.0] versus 1.3 [.8-2.4], both P < .05]. Multivariate analysis in the SR and pAF groups (n = 183) demonstrated that age, congestive heart failure, ANP, and BNP, but not ANP/BNP ratio, were independent predictors for detecting pAF. Receiver operating characteristic curve analysis further showed that area under the curve was similar between ANP and BNP (.76 and .80).
Conclusions: ANPmay be clinically useful for detecting pAF in ischemic stroke patients as well as BNP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Systemic Immune-Inflammation Index Predicts Long-Term Outcomes in Patients With Unstable Angina and Diabetes After Revascularization.
Rev Cardiovasc Med
August 2025
Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.
Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.
View Article and Find Full Text PDFPrevalence of Sleep-Disordered Breathing and Cheyne-Stokes Respiration in Patients With Atrial Fibrillation.
Rev Cardiovasc Med
August 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 113-8421 Tokyo, Japan.
Background: Limited data are available regarding the prevalence of sleep-disordered breathing (SDB), particularly Cheyne-Stokes respiration (CSR), in patients with atrial fibrillation (AF) and left ventricular (LV) systolic dysfunction. Thus, this study aimed to investigate the prevalence of SDB and CSR, as well as the factors associated with these conditions, in patients with AF without LV systolic dysfunction.
Methods: Patients with paroxysmal and non-paroxysmal AF underwent echocardiography and cardiorespiratory polygraphy.
Development and validation of a novel score to predict adverse outcomes in paediatric congenital mitral regurgitation (PRIMARY): a multicentre cohort study.
EClinicalMedicine
October 2025
Department of Cardiothoracic Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, China.
Background: Paediatric patients who underwent surgery for mitral regurgitation (MR) have a high risk of recurrence or death; however, no prediction tool has been developed to risk-stratify this challenging subpopulation.
Methods: In this multicentre cohort study, paediatric patients undergoing surgery for congenital MR in Shanghai Children's Medical Center in January 1st, 2009-December 31st, 2022 were included for analysis while those had a combination with infective endocarditis, anomalous left coronary artery from the pulmonary artery, rheumatic valvular disease, connective tissue disease, or single ventricle were excluded. A Cox regression model predictive of the primary outcome (a composite of mortality or mitral valve [MV] re-operation) was derived and converted to a point-based risk score.
Mechanisms of intrinsic osmolality and sodium detection by magnocellular neurosecretory neurons.
J Neuroendocrinol
September 2025
Center for Research in Neuroscience, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
The maintenance of extracellular fluid (ECF) osmolality and sodium concentration ([Na]) near optimal "set point" values sustains physiological functions and prevents pathological states such as hypo- and hypernatremia. The peptide hormones vasopressin (antidiuretic hormone) and oxytocin (a natriuretic hormone in rats) play key roles in this process. These hormones are synthesized by hypothalamic magnocellular neurosecretory cells (MNCs) that project to the neurohypophysis and are released into the systemic circulation in response to rises in ECF osmolality or [Na].
View Article and Find Full Text PDFOverall safety evaluation of the risk signals of sacubitril/valsartan: A postmarketing pharmacoepidemiology study from 2015 to 2024.
Arch Cardiovasc Dis
September 2025
Department of Orthopaedics, Shaoxing Keqiao Women & Children's Hospital, Shaoxing 312030, Zhejiang, China. Electronic address:
Background: Sacubitril/valsartan is a widely used cardiovascular agent characterized by its dual inhibition of the renin-angiotensin-aldosterone system and neprilysin. However, existing evidence on the safety of sacubitril/valsartan is primarily limited to clinical studies; this results in an inability to provide a timely update on associated adverse events.
Aim: To mine and systematically describe adverse events related to sacubitril/valsartan from September 2015 to June 2024 using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.